Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide with Decitabine and Camrelizumab in R/R Hodgkin Lymphoma
NCT04233294Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Feb 2020
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in classical Hodgkin lymphoma (cHL), sponsored by Chinese PLA General Hospital. Started Feb 2020; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT04233294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04233294.